DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Claims 1-9 and 11-21 as filed on 3/28/2025 are currently pending.
Applicant’s election without traverse of the Group I, claims 1-9, in the reply filed on 9/21/2026 is acknowledged.
Claims 11-21 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 9/21/2026.
Claims 1-9 as filed on 3/28/2025 are under examination in the instant office action.
Claim Rejections - 35 USC § 112
Claims 3 and 6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 3 is rendered indefinite by the phrase “steep of extracting black pepper is comprised of extracting hydrocarbon”. It is unclear as written whether “hydrocarbon” is an extracting solvent, or whether hydrocarbon is a product of extracting step (terpene oil). Specification par. 0025 discloses “hydrocarbon” as an extraction solvent that would include ethanol and ethyl acetate. However, ethanol and ethyl acetate are not hydrocarbons. Claim 3 is also unclear in the light of specification.
Claim 6 recites the limitation "supercritical fluid" derived from black pepper that is extracted with supercritical carbon dioxide. There is insufficient antecedent basis for this limitation in the claim 1.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-5 and 7-9 are rejected under 35 U.S.C. 103 as being unpatentable over US 2020/0199055 (Jansen et al) in view of Geddo et al (Nutrients, 2019, 11, article 2788, pages 1-14).
The cited document US 2020/0199055 (Jansen et al) discloses a method for producing a plant cannabinoid extract comprising beta-caryophyllene (BCP) and five or more other terpenes including α-pinene, ß-pinene, 3-carene, humulene, limonene and linalool (entire document including abstract, par. 0007 and table 5 on page 53).
The cited method comprises steps of:
Step of extracting plant material to produce a first extract comprising fat-soluble components (fig. 1C, par. 0128-0130; par.0092; par. 0152)
Steps of refining including “winterizing” (par. 186, item 445; par. 0201, par. 0246) the first extract with fat-soluble components to remove undesired components (fatty acids, gums, waxes) differentiated by solidification temperature; wherein winterizing comprises chilling the extract at temperature 4°C to 15°C and precipitating undesired components (see par. 0201); wherein low temperature provides for better selection of target extractives such as cannabinoids and terpenes while minimizing extraction of gums, waxes, chlorophylls (par. 0246); wherein the additional undesired components are further removed by filtering the winterized extract through activated carbon (par. 0246, lines 14-17);
Step of fractionally distilling the winterized fat-soluble components of the first extract to produce a plurality of plant derived lipid fractions including terpenes, caryophyllene, and cannabinoids (see par. 0259), wherein distillation temperature is 100°C or less (par. 0259, line 8) and distillation pressure is low or below atmospheric such as 10-450 torr (par. 0259, lines 11-14)l and;
Step of blending two or more of the lipid fractions to produce final plant cannabinoid extract by adding terpenes collected separately at distillation to the oil fraction with cannabinoids (par. 0281).
Thus, the cited method comprises the same major steps of as encompassed by claim 1 (extraction, winterization, fractionation by distillation and blending), wherein the steps are practiced at the same conditions as encompassed by claims 3-5 and 7-9. The final product made by the cited method comprises the same target components including beta-caryophyllene (BCP) and five or more other terpenes including α-pinene, ß-pinene, 3-carene, humulene, limonene and linalool (table 5 on page 53).
But the cited plant cannabinoid extract is made from cannabis plant and not from black pepper as recited in the pending claims; and the cited extract contains less of BCP then recited in claim 1.
However, it is known that black pepper plant contains the same target components including beta-caryophyllene (BCP) and five or more other terpenes including α-pinene, ß-pinene, 3-carene, humulene, limonene, linalool and sabinene; and that extract from black pepper provides for high content of BCP such as 87%; for example: see abstract and table 1, page 6, of the cited reference by Geddo.
Therefore, it would have been obvious to one having ordinary skill in the art at the time the claimed invention was filed to substitute a black pepper plant material for cannabis plant material in the method of US 2020/0199055 (Jansen et al) for producing a plant cannabinoid extract with beta-caryophyllene (BCP) and other terpenes
with a reasonable expectation of success in providing a plant extract with the same target components including high contents of beta-caryophyllene (BCP) and other terpenes including α-pinene, ß-pinene, 3-carene, humulene, limonene, etc because black pepper plant is known to contain the same extractive terpenes and as well as a high amount of BCP as evidenced by Geddo. One of skill in the art would have been motivated to use black pepper plant for extraction because it is known that extraction of black pepper plant provides for a higher amount of BCP than cannabis plant which is used for extraction in the method of US 2020/0199055 (Jansen et al).
Thus, the claimed invention as a whole was clearly prima facie obvious, especially in the absence of evidence to the contrary.
The claimed subject matter fails to patentably distinguish over the state art as represented be the cited references. Therefore, the claims are properly rejected under 35 USC § 103.
Claims 1-9 are rejected under 35 U.S.C. 103 as being unpatentable over US 2020/0199055 (Jansen et al) and Geddo et al (Nutrients, 2019, 11, article 2788, pages 1-14) as applied to claims 1-5 and 7-9 above, and further in view of US 9,744,200 (Tucker et al).
The cited references US 2020/0199055 (Jansen et al) and Geddo et al as above.
The cited US 2020/0199055 (Jansen et al) is silent about the use of supercritical carbon dioxide for exacting terpenes from plant materials.
However, the cited US 9,744,200 (Tucker et al) teaches the use of supercritical carbon dioxide for exacting terpenes and/or providing a terpene oil from plant materials (see abstract, see fig 1). The terpenes include beta-caryophyllene and others (col. 4, lines 43-46); the concertation of terpenes in terpene oil extracted by supercritical carbon dioxide can be 99% (col. 4, line 55); the terpene oil is further blended with cannabinoids extracted from plant materials (fig. 1) at any ratio (col. 2, lines 23-24), thereby, modifying contents of terpenes including BCP in the final plant cannabinoid extract.
Therefore, it would have been obvious to one having ordinary skill in the art at the time the claimed invention was filed to extract terpenes from plant materials by using supercritical carbon dioxide and further to adjust or to modify ratios of extracted fractions to optimize amounts of terpenes including BCP in the final products depending on a desired goal.
Thus, the claimed invention as a whole was clearly prima facie obvious, especially in the absence of evidence to the contrary.
The claimed subject matter fails to patentably distinguish over the state art as represented be the cited references. Therefore, the claims are properly rejected under 35 USC § 103.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to VERA AFREMOVA whose telephone number is (571)272-0914. The examiner can normally be reached Monday-Friday: 8.30am-5pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila Landau can be reached at (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Vera Afremova
October 27, 2026
/VERA AFREMOVA/ Primary Examiner, Art Unit 1653